Baxter Healthcare Corporation has recalled 13,502 vials of Bendamustine HCl Injection, 100mg/4mL (25mg/mL), a prescription chemotherapy medication. The recall was issued because the labels on some vials were found to be partially or completely peeling off, which could make it impossible to identify the drug. These vials were distributed nationwide across the United States to hospitals, clinics, and pharmacies.
If the label is missing or peeling, healthcare providers cannot verify the medication name, strength, or expiration date before use. This poses a risk of medication errors, potentially leading to the administration of the wrong drug or an incorrect dosage. No injuries or incidents have been reported to date.
Recall #: D-1103-2023. Total quantity affected: 13,502 vials.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.